Hamilton Thorne Ltd. (HTL.V)
| Previous Close | 1.5200 |
| Open | 1.5300 |
| Bid | 1.5300 x 0 |
| Ask | 1.5700 x 0 |
| Day's Range | 1.5300 - 1.5600 |
| 52 Week Range | 1.3100 - 2.1400 |
| Volume | |
| Avg. Volume | 52,981 |
| Market Cap | 225.938M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | 173.33 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Hamilton Thorne Announces Passing of Diarmaid Douglas-Hamilton
BEVERLY, Mass. and TORONTO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies ("ART") research, and cell biology markets, today announces the passing of Diarmaid Douglas-Hamilton, Cofounder and Chief Technology Officer of Hamilton Thorne. Diarmaid passed away on January 19 at age 82, at his lab in Beverly, MA, after a he
- GlobeNewswire
Hamilton Thorne Announces the Acquisition of Microptic, S.L.
• Strengthens Hamilton Thorne Footprint in Computer Assisted Semen Analysis (CASA) for the IVF clinic • Significantly expands expertise in artificial intelligence (AI) enabled product offerings • Expands direct sales and support platform for the Hamilton Thorne group’s product portfolio in Europe BEVERLY, Mass. and TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software a
- GlobeNewswire
Hamilton Thorne Reports Financial and Operational Results for the Quarter and Nine Months Ended September 30, 2022
Revenues up 6% for the quarter and 14% for the nine months despite supply chain issues and significant foreign currency swings Organic growth of 17% for the Quarter BEVERLY, Mass. and TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported financial and operational results for the quarter and nine
